Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC.AGIO · Entity 4499 | Chief Financial Officer | March 01, 2022 | March 03, 2022 |
| VERTEX PHARMACEUTICALS INC / MAVRTX · Entity 2875 | EVP and Chief Legal Officer | February 24, 2026 | February 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
AGIOS PHARMACEUTICALS, INC.
Report date March 01, 2022 · Filed March 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Restricted stock unitsSEC Table II · derivative / convertible security | Direct | 11,500 |
Reported balance
After 2022-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-03-01 · Grant · Acquired 11,500 · Balance 11,500 F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. |
| Stock options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $32.20 · Expires 2032-03-01 | Direct | 41,000 |
Reported balance
After 2022-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-01 · Grant · Acquired 41,000 · Balance 41,000 F3: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.
F2: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments.
F3: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter.
VERTEX PHARMACEUTICALS INC / MA
Report date February 24, 2026 · Filed February 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 13,659 |
Ending reported balance
After 2026-02-25 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-24 · Tax withholding · Disposed 1,144 · Balance 14,604 Row 2 · 2026-02-25 · Sale · Disposed 945 · Balance 13,659 F1: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. |
Filing footnotes · ownership attribution and instrument terms
F1: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CELGENE CORP /DE/
Report date November 20, 2019 · Filed November 22, 2019
Section 16 reporting ended · disclosed 2019-11-22. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $88.91 · Expires 2028-07-30 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-11-20 · Disposition to issuer · Disposed 4,687 · Balance 0 F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement. F1: This option was fully exercisable. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-20 · Disposition to issuer · Disposed 1,563 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Disposition to issuer · Disposed 6,719 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2019-11-20 · Disposition to issuer · Disposed 781 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2019-11-20 · Disposition to issuer · Disposed 8,000 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2019-11-20 · Disposition to issuer · Disposed 6,288 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
| Restricted Stock UnitSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 0 |
Reported balance
After 2019-11-20 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2019-11-20 · Disposition to issuer · Disposed 31,714 · Balance 0 F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock. F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was fully exercisable.
F2: In connection with the Agreement and Plan of Merger (the "Merger Agreement") dated January 2, 2019, by and among Celgene Corporation ("Celgene"), Bristol-Myers Squibb Company ("BMS"), and Burgundy Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of BMS ("Merger Sub"), pursuant to which Merger Sub will merge with and into Celgene, with Celgene surviving as a direct wholly owned subsidiary of BMS and upon the effective time of such merger (the "Effective Time"), these stock options were assumed by BMS and converted into options relating to BMS common stock (plus a payment of contingent value rights ("CVRs"), in some cases) in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
F3: Each restricted stock unit represents a contingent right to receive one share of Celgene common stock.
F4: Upon the Effective Time, these restricted stock units were assumed by BMS and converted into restricted stock units relating to BMS common stock and CVRs in accordance with the methodology and exchange ratio set forth in the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 25, 2026 Filed Feb 26, 2026 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 945 | $486.35 | $459,600.75 |
DisclosureSEC source: 0000875320-26-000108 · wk-form4_1772146913.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 13,659 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 23:01 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,144 | $485.11 | $554,965.84 |
DisclosureSEC source: 0000875320-26-000108 · wk-form4_1772146913.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,604 Read SEC document |
| February 18, 2026 Filed Feb 19, 2026 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,244 | $473.68 | $589,257.92 |
DisclosureSEC source: 0000875320-26-000084 · wk-form4_1771535316.xml · nonDerivative · entry 4 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,748 F2 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 2,476 | $489.46 | $1,211,902.96 |
DisclosureSEC source: 0000875320-26-000084 · wk-form4_1771535316.xml · nonDerivative · entry 3 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,992 F2 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,505 | $483.75 | $728,043.75 |
DisclosureSEC source: 0000875320-26-000084 · wk-form4_1771535316.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,468 Read SEC document |
| February 17, 2026 Filed Feb 19, 2026 21:08 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,135 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000084 · wk-form4_1771535316.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,973 F1 · shares: Restricted stock unit award that vests in installments beginning on February 20, 2027. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 988 | $499.00 | $493,012.00 |
DisclosureSEC source: 0000875320-26-000064 · wk-form4_1771449971.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,838 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 13, 2026 Filed Feb 18, 2026 21:26 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 2,993 | $487.76 | $1,459,865.68 |
DisclosureSEC source: 0000875320-26-000064 · wk-form4_1771449971.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,826 Read SEC document |
| February 11, 2026 Filed Feb 12, 2026 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,925 | $460.43 | $886,327.75 |
DisclosureSEC source: 0000875320-26-000040 · wk-form4_1770933137.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,819 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| February 10, 2026 Filed Feb 12, 2026 21:52 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,630 | $468.41 | $763,508.30 |
DisclosureSEC source: 0000875320-26-000040 · wk-form4_1770933137.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 22,744 Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 2,774 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000014 · wk-form4_1769462440.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,374 F2 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/12/2025 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest in installments beginning on 02/24/2026. Read SEC document |
| January 22, 2026 Filed Jan 26, 2026 21:20 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-26-000014 · wk-form4_1769462440.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,600 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 01/22/2026 and the shares will vest on 02/13/2026. Read SEC document |
| December 03, 2025 Filed Dec 5, 2025 21:06 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 347 | $449.00 | $155,803.00 |
DisclosureSEC source: 0000875320-25-000240 · wk-form4_1764968757.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,306 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| October 02, 2025 Filed Oct 3, 2025 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 694 | $404.21 | $280,521.74 |
DisclosureSEC source: 0000875320-25-000224 · wk-form4_1759522036.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,653 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/24/2025. Read SEC document |
| October 01, 2025 Filed Oct 3, 2025 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,259 | $400.00 | $503,600.00 |
DisclosureSEC source: 0000875320-25-000224 · wk-form4_1759522036.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,347 Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,657 | $455.06 | $754,034.42 |
DisclosureSEC source: 0000875320-25-000085 · wk-form4_1740000492.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,606 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024. Read SEC document |
| February 14, 2025 Filed Feb 19, 2025 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,504 | $463.46 | $697,043.84 |
DisclosureSEC source: 0000875320-25-000085 · wk-form4_1740000492.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,263 Read SEC document |
| February 12, 2025 Filed Feb 14, 2025 21:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,437 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000063 · wk-form4_1739567406.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,767 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/24/2026. Read SEC document |
| February 11, 2025 Filed Feb 12, 2025 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 3,433 | $459.87 | $1,578,733.71 |
DisclosureSEC source: 0000875320-25-000039 · wk-form4_1739396180.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,330 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024. F2 · price: Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $459.87 (range $459.83 to $460.00). Read SEC document |
| February 10, 2025 Filed Feb 12, 2025 21:36 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,632 | $467.98 | $763,743.36 |
DisclosureSEC source: 0000875320-25-000039 · wk-form4_1739396180.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,763 Read SEC document |
| February 04, 2025 Filed Feb 6, 2025 21:32 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,744 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-25-000014 · wk-form4_1738877513.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,395 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/07/2024 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/04/2025 and the shares will vest in installments beginning on 02/17/2025. Read SEC document |
| October 02, 2024 Filed Oct 3, 2024 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 999 | $461.66 | $461,198.34 |
DisclosureSEC source: 0000875320-24-000214 · wk-form4_1727986328.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,651 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/13/2024. Read SEC document |
| October 01, 2024 Filed Oct 3, 2024 20:12 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 630 | $466.84 | $294,109.20 |
DisclosureSEC source: 0000875320-24-000214 · wk-form4_1727986328.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 17,650 Read SEC document |
| February 12, 2024 Filed Feb 13, 2024 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 1,738 | $418.77 | $727,822.26 |
DisclosureSEC source: 0000875320-24-000047 · wk-form4_1707861402.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 18,280 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2023. F2 · price: Mr. Biller undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. F3 · price: Open market sales reported on this line occurred at a weighted average price of $418.77 (range $418.76 to $418.82). Read SEC document |
| February 09, 2024 Filed Feb 13, 2024 21:56 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 1,588 | $422.74 | $671,311.12 |
DisclosureSEC source: 0000875320-24-000047 · wk-form4_1707861402.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,018 Read SEC document |
| February 07, 2024 Filed Feb 8, 2024 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 4,743 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000022 · wk-form4_1707427717.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,606 F2 · shares: Restricted stock unit award that vests in installments beginning on 02/17/2025. Read SEC document |
| February 06, 2024 Filed Feb 8, 2024 21:28 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000875320-24-000022 · wk-form4_1707427717.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,863 F1 · shares: Represents earned performance shares with respect to a performance stock unit award granted on 02/01/2023 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/06/2024 and the shares will vest in installments beginning on 02/10/2024. Read SEC document |
| October 02, 2023 Filed Oct 3, 2023 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | SaleCommon Stock | 610 | $346.76 | $211,523.60 |
DisclosureSEC source: 0001209191-23-051408 · doc4.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 10,569 F1 · kind: Transaction made pursuant to Mr. Biller's company approved trading plan under Rule 10b5-1, which was entered into on 02/27/2023. Read SEC document |
| September 29, 2023 Filed Oct 3, 2023 20:07 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | Tax withholdingCommon Stock | 408 | $350.72 | $143,093.76 |
DisclosureSEC source: 0001209191-23-051408 · doc4.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 11,179 Read SEC document |
| February 01, 2023 Filed Feb 3, 2023 21:39 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 6,293 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006913 · doc4.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,587 F1 · shares: Restricted stock unit award that vests in installments beginning on 02/10/2024. Read SEC document |
| September 19, 2022 Filed Sep 21, 2022 20:10 UTC | VERTEX PHARMACEUTICALS INC / MA VRTX · Entity 2875 | GrantCommon Stock | 5,294 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-031641 · doc4.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · EVP and Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,294 F1 · shares: Restricted stock unit award that vests in installments beginning on 10/01/2022. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock options (right to buy) · Derivative | 41,000 | $0.00 Strike: $32.20 | $0.00 |
DisclosureSEC source: 0001439222-22-000031 · wf-form4_164634191545873.xml · derivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,000 Underlying: Common stock · 41,000 shares Expires 2032-03-01 F3 · derivative.exercise_date: This option was granted on March 1, 2022. The shares underlying this option vest as to 25% of the underlying shares on March 1, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:12 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000031 · wf-form4_164634191545873.xml · derivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,500 Underlying: Common stock · 11,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on March 1, 2022. Beginning on March 1, 2023, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 22, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,688 | $29.08 | $78,167.04 |
DisclosureSEC source: 0001439222-22-000018 · wf-form4_164565063350307.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,953 Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 8,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000018 · wf-form4_164565063350307.xml · derivative · entry 3 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,522 Underlying: Common stock · 8,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified regulatory milestone was determined to have been met on February 18, 2022, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| February 18, 2022 Filed Feb 23, 2022 21:10 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000018 · wf-form4_164565063350307.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,641 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000006 · wf-form4_164487285754334.xml · derivative · entry 3 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,333 Underlying: Common stock · 3,667 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,349 | $31.43 | $42,392.33 |
DisclosureSEC source: 0001439222-22-000006 · wf-form4_164487285754334.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,118 Read SEC document |
| February 10, 2022 Filed Feb 14, 2022 21:08 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 3,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-22-000006 · wf-form4_164487285754334.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,467 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000076 · wf-form4_163891189929319.xml · derivative · entry 3 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,753 Underlying: Common stock · 5,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F3 · derivative.exercise_date: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. F3 · derivative.expiration_date: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,823 | $35.88 | $65,405.78 |
DisclosureSEC source: 0001439222-21-000076 · wf-form4_163891189929319.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,800 Read SEC document |
| December 03, 2021 Filed Dec 7, 2021 21:18 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000076 · wf-form4_163891189929319.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · balance_after: Includes 830 shares purchased through the Company's employee stock purchase plan. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantStock option (right to buy) · Derivative | 44,000 | $0.00 Strike: $56.68 | $0.00 |
DisclosureSEC source: 0001439222-21-000004 · wf-form4_161316492476489.xml · derivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,000 Underlying: Common stock · 44,000 shares Expires 2031-02-10 F3 · derivative.exercise_date: This option was granted on February 10, 2021. The shares underlying this option vest as to 25% of the underlying shares on February 10, 2022, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 10, 2021 Filed Feb 12, 2021 21:22 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | GrantRestricted stock units · Derivative | 11,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-21-000004 · wf-form4_161316492476489.xml · derivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,000 Underlying: Common stock · 11,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. F2 · derivative.expiration_date: The restricted stock units were granted on February 10, 2021. Beginning on February 10, 2022, the shares underlying the restricted stock units will vest in three equal annual installments. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 23:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionRestricted stock units · Derivative | 5,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000071 · wf-form4_160738329299398.xml · derivative · entry 3 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,506 Underlying: Common stock · 5,753 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The restricted stock units were granted on December 3, 2019. Beginning on December 3, 2020, the shares underlying the restricted stock units will vest in three equal annual installments. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 23:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 1,707 | $45.87 | $78,300.09 |
DisclosureSEC source: 0001439222-20-000071 · wf-form4_160738329299398.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,040 Read SEC document |
| December 03, 2020 Filed Dec 7, 2020 23:21 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 5,753 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000071 · wf-form4_160738329299398.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
| April 14, 2020 Filed Apr 15, 2020 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Tax withholdingCommon stock | 2,529 | $40.64 | $102,778.56 |
DisclosureSEC source: 0001439222-20-000032 · wf-form4_158698240592447.xml · nonDerivative · entry 2 Biller Jonathan · CIK 0001744749 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,994 Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionPerformance share units · Derivative | 8,523 | $0.00 | $0.00 |
DisclosureSEC source: 0001439222-20-000032 · wf-form4_158698240592447.xml · derivative · entry 3 Biller Jonathan · CIK 0001744749 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,045 Underlying: Common stock · 8,523 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. F2 · derivative.exercise_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. F2 · derivative.expiration_date: The PSUs vest as to one-third of the underlying shares of common stock, upon the achievement of each of three specified research, regulatory and commercial milestones, subject to continued service. The performance criteria for the specified commercial milestone was determined to have been met on April 13, 2020, resulting in the vesting of the PSUs as to one-third of the underlying shares of common stock on that date. Vested shares will be delivered to the reporting person within three business days after such shares become vested. Read SEC document |
| April 13, 2020 Filed Apr 15, 2020 20:27 UTC | AGIOS PHARMACEUTICALS, INC. AGIO · Entity 4499 | Exercise / conversionCommon stock | 8,523 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001439222-20-000032 · wf-form4_158698240592447.xml · nonDerivative · entry 1 Biller Jonathan · CIK 0001744749 · Chief Legal Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,523 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance share unit represents a contingent right to receive one share of the issuer's common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.